Literature DB >> 22801846

Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration.

John P Campbell, Susan B Bressler, Neil M Bressler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22801846     DOI： 10.1001/archophthalmol.2011.2480

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  21 in total

1.  Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.

Authors:  Cheolmin Yun; Jaeryung Oh; Jaemoon Ahn; Soon-Young Hwang; Boram Lee; Seong-Woo Kim; Kuhl Huh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-19       Impact factor: 3.117

Review 2.  Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis.

Authors:  G Pron
Journal:  Ont Health Technol Assess Ser       Date:  2014-08-01

3.  Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration.

Authors:  Boram Lee; Gyeongmin Yoo; Cheolmin Yun; Jaeryung Oh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-31       Impact factor: 3.117

Review 4.  Recent developments in the treatment of age-related macular degeneration.

Authors:  Frank G Holz; Steffen Schmitz-Valckenberg; Monika Fleckenstein
Journal:  J Clin Invest       Date:  2014-04-01       Impact factor: 14.808

5.  [Design of the ORCA module in the OCEAN study : Evaluation of SD-OCT results in daily routine practice].

Authors:  B Heimes; T Schick; C K Brinkmann; A Wiedon; B Haegele; B Kirchhof; F G Holz; D Pauleikhoff; F Ziemssen; S Liakopoulos; G Spital; S Schmitz-Valckenberg
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

6.  Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.

Authors:  M Buckle; A Lee; Q Mohamed; E Fletcher; A Sallam; R Healy; I Stratton; A Tufail; R L Johnston
Journal:  Eye (Lond)       Date:  2015-01-16       Impact factor: 3.775

7.  Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs.

Authors:  Justine R Smith; Larry L David; Binoy Appukuttan; Phillip A Wilmarth
Journal:  Am J Ophthalmol       Date:  2018-03-17       Impact factor: 5.258

8.  Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.

Authors:  Nathan G Lambert; Xiaohui Zhang; Ruju R Rai; Hironori Uehara; Susie Choi; Lara S Carroll; Subrata K Das; Judd M Cahoon; Brian H Kirk; Blaine M Bentley; Balamurali K Ambati
Journal:  Exp Eye Res       Date:  2016-01-13       Impact factor: 3.467

9.  Polypoidal Choroidal Vasculopathy after Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: A Case Report with Long-Term Follow-Up.

Authors:  Alexandra Steinemann; Laura Hoffmann; Katja B Hatz
Journal:  Case Rep Ophthalmol       Date:  2021-04-30

Review 10.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Authors:  Ursula Schmidt-Erfurth; Victor Chong; Anat Loewenstein; Michael Larsen; Eric Souied; Reinier Schlingemann; Bora Eldem; Jordi Monés; Gisbert Richard; Francesco Bandello
Journal:  Br J Ophthalmol       Date:  2014-09       Impact factor: 4.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.